GlassScriptPhysician profile
Elliot L Smith
NPI 1396741492
$882.66
in general payments reported to CMS, 2019-2025
20 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $56.28 · 2024: $386 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $143.72 | 2025 | Watchman |
| Abbvie INC. | $88.05 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $79.99 | 2024-2025 | Airsupra, Tezspire |
| Lilly USA, LLC | $79.58 | 2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $62.76 | 2024-2025 | Repatha, Tezspire, Otezla |
| Exact Sciences Corporation | $50.54 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abiomed | $42.39 | 2025 | |
| Lundbeck LLC | $36.99 | 2024-2025 | Rexulti |
| Stryker Corporation | $35.45 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.90 | 2024-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $31.77 | 2024 | Eterna, Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $29.01 | 2023 | Linzess |
| Medtronic, INC. | $27.27 | 2023 | Hawkone |
| Novo Nordisk INC | $26.85 | 2025 | Ozempic |
| Pfizer INC. | $26.37 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.37 | 2025 | Ultomiris |
| Verona Pharma, INC. | $20.90 | 2025 | Ohtuvayre |
| Eisai INC. | $17.55 | 2024 | |
| Glaxosmithkline, LLC. | $16.04 | 2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $13.16 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.